Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Guérin.

@article{Mostafid2015TherapeuticOI,
  title={Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Gu{\'e}rin.},
  author={A. Hugh Mostafid and Juan Palou Redorta and Richard Joel Sylvester and Johannes Alfred Witjes},
  journal={European urology},
  year={2015},
  volume={67 3},
  pages={359-60}
}
Optimal management of high-risk non-muscle-invasive bladder cancer during the current bacillus Calmette-Guérin (BCG) shortage is challenging. Although no evidence-based guidelines exist for this specific situation, current management options can be adapted for when BCG supplies are limited or when BCG is unavailable. 
Recent Discussions
This paper has been referenced on Twitter 74 times over the past 90 days. VIEW TWEETS

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
15 Extracted Citations
9 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 15 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-9 of 9 references

Maintenance BCG immunotherapy for recurrent TA,T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study

  • DK Lamm, BA Blunemstein, JD Crissman
  • J Urol 2000;163:1124–9
  • 2000
1 Excerpt

Approach for consideration to address shortage of bacillus Calmette - Guérin ( BCG ) . Bladder Cancer Canada Web site

  • PU Malmström, RJ Sylvester, CrawfordDE

Mould at Toronto plant may affect supplies of cancer drug . Canadian Press Web site

  • C Gan, H Mostafid, MS Khan, DJ Lewis

Similar Papers

Loading similar papers…